Renal and cardiac effects of the PDE9 inhibitor BAY 73–6691 in 5/6 nephrectomized rats-Reference-Cited by-同舟云学术

Renal and cardiac effects of the PDE9 inhibitor BAY 73–6691 in 5/6 nephrectomized rats

Published:2024-02-02 Issue:5 Volume:476 Page:755-767
ISSN:0031-6768
Container-title:Pflügers Archiv - European Journal of Physiology
language:en
Short-container-title:Pflugers Arch - Eur J Physiol

Author:

Chen Xin,Delić Denis,Cao Yaochen,Zhang Zeyu,Wu Hongwei,Hasan Ahmed A.,Gaballa Mohamed M. S.,Yin Lianghong,Krämer Bernhard K.,Klein Thomas,Shi Xin,He Ben,Shen Linghong,Hocher Berthold

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00424-024-02915-2.pdf

Reference46 articles.

1. Almeida CB, Scheiermann C, Jang JE et al (2012) Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood 120(14):2879–2888. https://doi.org/10.1182/blood-2012-02-409524

2. Azevedo MF, Faucz FR, Bimpaki E et al (2014) Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 35(2):195–233. https://doi.org/10.1210/er.2013-1053

3. Barbosa MC, de Jesus TE, dos Santos TN, dos Santos, et al (2016) The effect of a selective inhibitor of phosphodiesterase-9 on oxidative stress, inflammation and cytotoxicity in neutrophils from patients with sickle cell anaemia. Basic Clin Pharmacol Toxicol 118(4):271–278. https://doi.org/10.1111/bcpt.12487

4. Boustany-Kari CM, Harrison PC, Chen H et al (2016) A soluble guanylate cyclase activator inhibits the progression of diabetic nephropathy in the ZSF1 rat. J Pharmacol Exp Ther 356(3):712–719. https://doi.org/10.1124/jpet.115.230706

5. Carlstrom M (2021) Nitric oxide signalling in kidney regulation and cardiometabolic health. Nat Rev Nephrol 17(9):575–590. https://doi.org/10.1038/s41581-021-00429-z